



Profiel van de inschrijver

European AIDS Treatment Group

Inschrijvingsnummer in het register: **49959188061-85**

Inschrijvingsdatum: **13/02/2012 16:32:26**

Laatste (gedeeltelijke of jaarlijkse) actualisering op: **15/04/2021 08:41:12**

De laatste jaarlijkse update vond plaats op: **11/05/2020 15:19:20**

Volgende jaarlijkse actualisering op: **11/05/2021**



Inschrijver: Organisatie of zelfstandige

Naam organisatie:

European AIDS Treatment Group

Acroniem:

EATG

Rechtsvorm:

NGO

Website:

<http://www.eatg.org>



Inschrijvingscategorie

Categorie

III - Niet-gouvernementele organisaties

Meer specifiek:

Niet-gouvernementele organisaties, platformen & netwerken e.d.



Contactgegevens

Gegevens van het hoofdkantoor

Mettmanner Strasse, 24-26
40233 Duesseldorf
DUITSLAND

Telefoon:

(+32)26269640

Contactgegevens van het kantoor van de organisatie in België:

Interoffices Avenue des Arts 56-4c
1000 Brussels
BELGIË

Telefoon:

(+32)26269640



Wettelijk verantwoordelijke

Voornaam, Achternaam:

Mijnheer Ricardo Fernandes

Functie:

Chair

 Contactpersoon voor EU-zaken**Voornaam, Achternaam:**

Mijnheer Pieter Vanholder

Functie:

Executive Director

 Doelstellingen en taken**Doelstellingen en taken van de organisatie:**

For 2020-2025, EATG's mission is:

Equitable, speedy and sustainable access to:

- effective treatments and holistic care for all people living with HIV and associated infections and morbidities, and
- effective prevention and diagnosis for all communities affected by HIV and associated infections and morbidities.

EATG will focus on 3 Programme Areas:

Quality of Life In line with its mission to advance equitable, speedy and sustainable access to effective treatments and holistic care for all people living with HIV and associated infections and morbidities.

Combination Prevention

In line with its mission to advance equitable, speedy and sustainable access to effective prevention and diagnosis for all.

Partners in Science

In line with its mission to advance equitable, speedy and sustainable access to effective treatments and holistic care for all people living with HIV and associated infections and morbidities.

Uw organisatie is actief op de volgende niveaus:

Europees

 Onder het register vallende activiteiten**Belangrijkste wetgevingsvoorstellen of beleidsgebieden waarop uw organisatie zich richt:**

Pharmaceutical Strategy - Timely patient access to affordable medicines : consultation on the roadmap

- Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the establishment of a Programme for the Union's action in the field of health –for the period 2021-2027 and repealing Regulation (EU) No 282/2014 (“EU4Health Programme”)
- COM/2020/405 final and European Parliament EU4Health draft report
- Communication COM/2018/233 final on enabling the digital transformation of health and care in the Digital Single Market; empowering citizens and building a healthier society
- Cancer mission recommendation
- EU drug policy post-2020

Previous input/submissions:

- COMMISSION STAFF WORKING DOCUMENT SWD(2018) 387 final on Combatting HIV/AIDS, viral hepatitis and tuberculosis in the European Union and neighbouring countries - State of play, policy instruments and good practices
- Submission to EMA Consultation on the Role of big data for evaluation and supervision of medicines in the EU
- submission to EU drugs strategy 2013-20 – evaluation consultation(December 2019-Feb 2020);
- submission to EU Drugs Agenda and Action Plan consultation in June-July 2020
- ECDC: Public health guidance on HIV, hepatitis B and C testing in the EU/EEA: input as expert, 2018

Relevante activiteiten op het gebied van beleidsuitvoering, public relations en communicatie zoals projecten, evenementen en publicaties:

EU Civil Society forum on HIV, TB and Hepatitis relaunch and secretariat with AAE, EHRA, Correlations, TBEC.

The EMERGE project (Evaluating mHealth technology in HIV to improve Empowerment and healthcare utilisation: Research and innovation to Generate Evidence for personalised care) is a mHealth platform to enable self-management of HIV in patients with stable disease. The EATG produced a brief on overcoming barriers to the implementation m-health solutions. On 2 September 2020, a multi-stakeholder meeting on the future of M-health in Europe was organised, drawing on the EMERGE project findings. The meeting also included a discussion on the EMERGE, mHealth and health systems in the EU and lessons from the COVID-19 Crisis and the role of digital pathways in HIV prevention and care. platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to key healthcare providers. EATG will be acting as community partner, supporting standards for HIV care and guidelines for routine monitoring both in the involved countries and more broadly across the EU and potentially wider.

ESTICOM – EUROPEAN SURVEYS AND TRAININGS TO IMPROVE MSM COMMUNITY HEALTH aims to strengthen the community response and raise awareness about the persisting legal, structural, political and social barriers hindering a more effective response to the syndemics of HIV, hepatitis viruses B and C, and other STI among MSM. The main activities include surveys among MSM (EMIS2017) and Community Based Health Workers (ECHOES) as well as a training programme for Community Health Workers intended to be adaptable for all EU countries.

HIVACAR – EVALUATING A COMBINATION OF IMMUNE-BASED THERAPIES TO ACHIEVE A FUNCTIONAL CURE OF HIV INFECTION. The project aims to change the current paradigm of HIV treatment by obtaining a functional cure for HIV thanks to effectively targeting residual virus replication and viral reservoirs.

EHVA – EUROPEAN HIV VACCINE ALLIANCE, AN EU PLATFORM FOR THE DISCOVERY AND EVALUATION OF NOVEL PROPHYLACTIC AND THERAPEUTIC VACCINE CANDIDATES. Project aims: To develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials.

EFOEUPATI - Ensuring the future of EUPATI beyond 2020 aims to ensure the sustainability of the results of the EUPATI project, to develop sustainable models of collaboration to ensure this, and put into place the infrastructure required for these to work, building on those already established under IMI-EUPATI.

PARADIGM - Patients Active in Research and Dialogues for an Improved Generation of Medicines – This IMI project aims to provide a framework that allows structured, meaningful, sustainable and ethical patient engagement throughout three key decision-making points of the development of medicinal products: (i) the research priority setting; (ii) the design of clinical trials and (iii) the early dialogues with regulators and HTA bodies. The work builds upon previous initiatives such the European Patients' Academy (EUPATI) and Patient Focused Medicine Development (PFMD).

Lijst van vergaderingen met de Europese Commissie ⓘ :

 PDF file

Bijdragen aan openbare raadplegingen ⓘ :

Alles inklappen/uitklappen

 Pharmaceutical Strategy - Timely patient access to affordable medicines

 Evaluation of the EU Drugs Strategy 2013-2020

 Evaluation of the EU Drugs Strategy 2013-2020

Lijst van bijdragen aan routekaarten ⓘ :

N/A

Deelname aan EU-structuren en -platforms

Interfractiewerkgroepen et niet-officiële groeperingen (Europees Parlement) ⓘ :

N/A

Deskundigengroepen van de Commissie en andere vergelijkbare entiteiten (Europese Commissie) ⓘ :

Alles inklappen/uitklappen

E02681 Commission expert group - Civil Society Forum on Drugs *Type C member*

Aanvullende informatie:

Achievements:

EATG has been at the forefront of community involvement in treatment development in HIV and co-infections. Our models of community involvement are shared with patient organisations beyond the HIV and co-infections field. EATG has been leading on innovative techniques such as biomedical prevention and HIV cure research.

EATG has been actively involved in setting up the EU Civil Society Forum on HIV, hepatitis and TB. Currently we are playing a leading role in the reform of the CSF.

In 1997 EATG created the European Community Advisory Board (ECAB) to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis. Today and in the coming years, these ECABs will remain one of EATG's core activities. This model of high-level scientific platform has been copied by other national and international community groups and networks (e.g. Portuguese CAB, EECA CAB, TB CAB, Positive Council Switzerland etc.)

Via our 'Sitges' meetings, EATG has driven the community input in HCV cure development.

EATG provides capacity building to different stakeholders, thus supporting better networking (especially in Central and Eastern Europe), increased capacity of PLHIV and health care providers, but also – via follow up activities – direct involvement of these people in new scientific and policy activities.

Population(s) served:

The European AIDS Treatment Group (EATG) is a patient-led NGO that advocates for the rights and interests of people living with or affected by HIV/ AIDS and related co-infections within the WHO Europe region. It is a network of more than 170 nationally based members from 47 countries in Europe. Our members are PLHIV and representatives of different communities affected by HIV/AIDS and co-infections. EATG represents the diversity of more than 2.3 million people living with HIV (PLHIV) in Europe as well as those affected by HIV/AIDS and co-infections.

Our members are representatives of different communities affected by HIV/AIDS in Europe. Our members are expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena.

EATG has close links with groups and organisations within the area of sex work, drug use, MSM, migrants, prisoners etc.. Our work is also in close collaboration with organisations that work on related topics such as vaccine development, prevention, liver disease, sexual health or human rights issues such as stigma and discrimination.

Involvement of PLWH:

EATG is a membership driven organisation. Our members are all members of the General Assembly (GA), the highest decision-making body of the EATG. A major part of our members are PLHIV. The GA is called at least annually by the Board of Directors (BoD). The GA elects the members of the BoD and other bodies. Directors are elected for a period of two years.

HIV positive members are also represented within each part of the structure (selected via democratic systems): Programme Chairs; BoD members, staff and other internal positions. EATG has 3 Programme Areas: Quality of Life, Combination Prevention and Partners in Science. Members become active within one or more of the Programmes, as part of designated Programme Committees or ad hoc task groups. EATG regularly organises consultations with its members and other groups. We actively support the GIPA principle.

Members are the main drivers of our strategic development. With support from the office members, they draft our long-term strategy, set priorities etc. We have many HIV-positive members involved as representatives within different structures and positions such as steering committees, scientific committees, and advisory boards.

Aantal personen dat betrokken is bij de hierboven vermelde activiteiten

Aantal betrokken medewerkers van de organisatie in percentages van een volledige baan:

100%: 0 75%: 0 50%: 0 25%: 6

Aantal betrokken medewerkers:

6

Voltijdequivalenten (FTE):

1,5

Aanvullende informatie:

We are a voluntary organisation with over 170 members from over 45 countries within and outside Europe. Our full-time Programme Manager works approx. 1/3 of her time on transparency register activities.

Geaccrediteerd voor toegang tot de gebouwen van het Europees Parlement

Voornaam	Achternaam	Begindatum	Einddatum
Pieter	VANHOLDER	15/05/2020	31/05/2021
Ann Isabelle	von Lingen	13/05/2020	12/05/2021

Interessegebieden

Interessegebieden van de organisatie:

- Justitie en grondrechten
- Onderwijs en opleiding
- Onderzoek en innovatie
- Volksgezondheid

Lidmaatschap en aangesloten organisaties

Totaal aantal aangesloten natuurlijke personen:

154

Aangesloten organisatie:

n/a

De organisatie heeft leden of is vertegenwoordigd in de volgende landen:

- BELGIË
- BULGARIJE
- CYPRUS
- DENEMARKEN
- DUITSLAND
- ESTLAND
- FRANKRIJK
- GRIEKENLAND
- HONGARIJE
- IERLAND
- ITALIË

- KROATIË
- LETLAND
- LITOUWEN
- LUXEMBURG
- MALTA
- NEDERLAND
- OOSTENRIJK
- POLEN
- PORTUGAL
- ROEMENIË
- SLOVENIË
- SPANJE
- TSJECHIË
- ALBANIË
- ARMENIË
- BOSNIË EN HERZEGOVINA
- CANADA
- GEORGIË
- ISRAËL
- KIRGIZIË
- MOLDAVIË
- NOORD-MACEDONIË
- OEKRAÏNE
- OEZBEKISTAN
- RUSLAND
- SERVIË
- TADZJIKISTAN
- TURKIJE
- VERENIGD KONINKRIJK
- VERENIGDE STATEN
- ZWITSERLAND

Lidmaatschap van verenigingen/(con)federaties/netwerken of andere instanties:

EU Civil Society Forum (CSF) on HIV , TB and Hepatitis ;
 EU Civil Society Forum on Drugs
 WHO Regional Coordination Committee on HIV, TB and Hep
 AIDS Action Europe;
 European Public Health Alliance (EPHA);
 European Forum for Good Clinical Practice (EFGCP)
 European Patient Forum (EPF)
 Platform for Cooperation with undocumented migrants (PICUM)
 ILGA – Europe
 International Committee on Rights of Sex Workers (ICRSE)

Financiële gegevens

Boekjaar:

01/2019 - 12/2019

Maak een raming van de jaarlijkse kosten die verband houden met de onder het register vallende activiteiten:

25.000 € en 49.999 €

Totaalbudget:

1.173.197 €

waarvan gefinancierd door de overheid:

233.563 €

Meest recente financiële gegevens over van de EU-instellingen ontvangen gelden:

Aanbestedingen:

€

Bron:

Subsidies:

233.563 €

Bron:

H2020 IMI

- nationale overheid:

€

- subnationale overheden:

€

waarvan uit andere bronnen:

939.634 €

- giften:

547.312 €

- contributies van de leden:

0 €

- recoverable costs :

4.072 €

- other projects :

374.742 €

- interest :

358 €

- membership fees :

4.500 €

- other :

8.650 €

Overige financiële en andere informatie over uw organisatie die relevant is voor de transparantie: **Gedragscode**

Door zich in te schrijven heeft de organisatie ingestemd met de gedragscode van het transparantieregister.